Today, we are honored to host Dr. Sara Naseri, CEO and Co-Founder of Qvin, a pioneering figure in women’s health innovation. In this session, we will explore the groundbreaking Q-Pad technology, the ...
The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...
The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA ...
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven ...
Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform ...
Nektar Therapeutics announced promising results from a Phase 2 study of its experimental drug NKTR-255, which improved ...
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.
Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...
The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback